AGM 2021

May 21, 2021

Good day, and welcome to the 2021 Fathom Pharmaceuticals Annual Shareholders Meeting. I would now like to turn the meeting over to Fathom's President and Chief Executive Officer, Teri Curran. Ms. Curran, please go ahead. Good morning, and welcome to the 2021 Annual Shareholders Meeting of FASM Pharmaceuticals. I'm Teri Curran, President and Chief Executive Officer of FASM. It's my pleasure to welcome you here today for our 2nd Annual Shareholders Meeting and to introduce the Chairman of Fathom's Board of Directors, Doctor. Tachi Yamada. Tachi? Thank you, Terry, and welcome everyone. Thank you for joining us today. We're excited to be hosting our virtual meeting, which allows us to be more inclusive and reach a greater number of our shareholders. We have shareholders attending via the web portal. As is our custom, we will conduct a business portion of our meeting first and answer questions at the end of the meeting. Any unanswered questions will be addressed on the Investor Relations section of our corporate website after the meeting. To help us conduct an orderly meeting, we ask that shareholders abide by the rules of conduct available through the link on the webcast screen. It's now shortly after 10:45 a. M. Eastern Time on May 21, and this meeting is officially called to order. In light of the virtual meeting format, the polls are now open and shareholders can vote by clicking on the Vote Here button on the bottom of the webcast screen. Members of Fathom's Board of Directors are attending today's meeting through this webcast. Also attending through this webcast are members of Fathom's senior management team and a representative of Ernst and Young LLP, the company's registered public accountant. Now it's my pleasure to introduce Fathom's General Counsel and Corporate Secretary, Larry Miller. Larry will act as Secretary of the meeting and will discuss some procedural matters with you. Thank you, Tachi. Please note that this meeting is being recorded and will be available for replay at the website www.virtualshareholdermeting.com/pat 20 21. However, no one attending the webcast is permitted to use any audio recording device. Finally, the company has appointed me to act as the Inspector of Election and earlier today I took the Inspector of Election Oath. The agenda and rules of conduct are posted with other meeting materials at the bottom of the webcast screen. The procedures we're following today are simple and are designed to ensure that we have a fair and orderly meeting. As Tachi explained, the polls are open. Most of you have already voted by proxy and the proxy votes have been tallied. If you want to vote now or change your vote, you can click on the vote or vote here button at the bottom of the webcast screen. The polls will stay open until the conclusion of the review of the matters to be voted on. After the formal meeting has been adjourned, we'll provide time for general questions. Only validated stockholders may ask questions in the designated field on the web portal. Your question will not be visible to other participants. Out of consideration for others, please limit yourself to one question. Please note this meeting is being recorded. However, as I mentioned earlier, please do not use any webcast or other audio recording device. This meeting is being held pursuant to proper notice. 31,321,613 shares of common stock were outstanding and entitled to vote at this meeting as of March 26, 2021, the record date of this meeting set by the company's Board of Directors. Propsies representing a majority of these shares have been received and therefore a quorum is present and the meeting should proceed. We will now review the matters to be voted on. Proposal 1 is the election of 2 Class 2 Directors. The current Board of Directors is nominated Michael F. Kola and Asit Karik, MD, PhD, for election as directors to hold office until the 2024 Annual Meeting of Shareholders or until their successors are duly elected and qualified. Proposal 2 is the ratification of Ernst and Young LLP as the company's independent registered public accounting firm for the fiscal year ending December 31, 2021. Now that we've reviewed the matters to be voted on at the meeting and the polls for the 2021 Fallon Pharmaceuticals Annual Shareholders Meeting are closed. Larry, do we have preliminary voting results? Yes, Tachi, we do. The preliminary vote report shows that the nominees for election to the Board have been duly elected and the ratification of Ernst and Young LLP as the company's independent registered public accounting firm has received sufficient 4 votes to be approved. We'll be reporting the final vote results in a Form 8 ks to be filed within 4 business days following this meeting. Thank you, Larry. Now we would like to respond to shareholder questions. Please note, only questions that are germane to the meeting will be addressed. Questions not addressed at today's meeting will be addressed on the Investor Relations section of our corporate website after the meeting. It appears that there are no shareholder questions to be addressed at today's meeting. There being no further business to come before the meeting, the 2021 Annual Meeting of Shareholders of Pfazen Pharmaceuticals is now adjourned. Thank you all for joining us today. This concludes Fathom Pharmaceuticals 2021 Annual Shareholder Meeting. Thank you for joining us. You may now disconnect.